Trisalus Life Sciences, Inc. · NASDAQ:TLSI
Trisalus Life Sciences — SPAC Merger (November 2022)
14 slides from Trisalus Life Sciences's SPAC merger presentation, Nov 21, 2022
Slide 1: Pressure Enabled Regional Immuno-oncology Trials Update
Noire sciences: Pressure Enabled Regional Immuno-oncology i ia Trials Update November 2022 © 2022 TriSalus™ Life Sciences. All Rights Reserved. Strictly Confidential. Not for Distribution,
Slide 2: Update on the PERIO 01 and PERIO 02 Clinical Studies
Update on the PERIO 01 and PERIO 02 Clinical Studies First-in-human experience in patients with liver tumors well- iw tolerated, with no serious adverse events related to TriNav® or procedure as monotherapy or in combination with checkpoint inhibitors https://periotrial.com PERIO 01 for uveal melano
Slide 3: Upcoming Milestones
Upcoming Milestones More Pivotal Data Expected in Next 6 Months January 2023 + PERIO 01 and PERIO 02 SD-101 + dual checkpoint inhibitor cohort November 2022 + Initial biopsy data March 2023 + PERIO SD-101 June 2023 + American Society of Clinical readout interventional radiology Oncology + Society of
Slide 4: Pressure-Enabled Regional Immuno-Oncology Clinical Studies
Pressure-Enabled Regional Immuno-Oncology PERIO 01 and PERIO 02 Clinical Studies Evaluating SD-101 in combination with checkpoint inhibitors in adults with uveal melanoma liver metastases, advanced hepatocellular carcinoma, and advanced intrahepatic cholangiocarcinoma Overview Both studies initiated
Slide 5: Clinical Study Overview
PERIO 01 and PERIO 02 Clinical Study Overview PHASE 1 STUDY DESIGN 25 of 27 Cohort A x Enrollment Completed patients enrolled had received one SD-101 Single AgentDe . or more lines of prior therapy ea Cohort B Enrolling at 4mg SD-101 + Anti-PD-1 Dose Escalation’ 8mg January Initiation Cohort C SD-10
Slide 6: Update: First In-Human Experience
PERIO 01 and PERIO 02 Update: First In-Human Experience Well-Tolerated First-in-human experience consistent with hypothesis that TriNav® can achieve high liver SD-101 levels with limited systemic exposure Cohort A 4 mg SD-101 Plasma PK + High SD-101 levels in liver following 300 Be hel . ‘. . = 102-
Slide 7: SD-101 Dual Mechanism — MDSC Elimination and Broad Immune Cell Activation
SD-101 Dual Mechanism — MDSC Elimination and Broad Immune Cell Activation Reversing immunosuppression to enhance tumor responsiveness*? sp-101 Liver and pancreatic ON tumors are unresponsive due to immunosuppression wnstighvatre” | MOSCer a ed | — ‘Activation of adaptive and Innate immune systems >
Slide 8: Data Supports Hypothesis that PEDD Can Enable SD-101 to Have Broad Immune Effects
Data Supports Hypothesis that PEDD Can Enable SD-101 to Have Broad Immune Effects in Liver Tumors and Eliminate MDSC SD-101 Infusion With TriNav® Demonstrated Cytokine Induction and MDSC Elimination Trend of increasing serum IFNg levels following infusion of 4 of 4 patients with available immunofluo
Slide 9: Immunocore: ctDNA Predicted Long-term Survival in Uveal Melanoma
Immunocore: ctDNA Predicted Long-term Survival in Uveal Melanoma Extent of circulating tumor DNA clearance from blood following immunotherapy treatment predicted long term survival in Immunocore clinical trial" 1.00 tetDNA clearance = |decreased risk of death naturemedicine CIDNA cleared 4.00 g 07 C
Slide 10: Circulating Tumor Cells and ctDNA Decreased in Most Patients Following SD-101 Infusions
Circulating Tumor Cells and ctDNA Decreased in Most Patients Following SD-101 Infusions at 2 mg Dose Level Data pending at higher dose levels Change in CTC Levels Change in ctDNA Levels 4 of 7* patients with circulating tumor cell decreases 3 of 5* patients with circulating tumor DNA decreases ActDN
Slide 11: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain “forward-looking statements” within the meaning of the United States federal securities laws regarding MedTech Acquisition Corporation ("MTAC"y's or TriSalus Life Sciences, Inc. (TriSatus'y’s , hopes, beliefs, assump! or regarding the fut
Slide 12: Changes and Additional Information in Connection with SEC Filing
Changes and Additional Information in Connection with SEC Filing The information in this presentation has not been reviewed by the SEC and certain information may not comply in certain respects with SEC rules. MTAC intends to file a registration statement on Form S-4 (the “Registration Statement’) t
Slide 13: Use of Data
Use of Data The data contained herein is derived from various internal and external sources. Neither MedTech nor TriSalus has independently verified the accuracy or completeness of the information derived from external sources. Any market data in the presentation involves a number of assumptions and
Slide 14: TriSalus Life Sciences
A TriSalus LIFE SCIENCES® © 2022 TriSalus™ Life Sciences. All Rights Reserved. Strictly Confidential. Not for Distribution.